The immune response to cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients

被引:24
|
作者
Ciaurriz, Miriam [1 ]
Zabalza, Amaya [1 ,2 ]
Beloki, Lorea [1 ]
Mansilla, Cristina [1 ]
Perez-Valderrama, Estela [1 ]
Lachen, Mercedes [1 ]
Bandres, Eva [1 ,2 ,3 ]
Olavarria, Eduardo [1 ,4 ]
Ramirez, Natalia [1 ]
机构
[1] IDISNA Navarras Hlth Res Inst, Oncohematol Res Grp, Navarrabiomed Fdn Miguel Servet, Navarra 31008, Spain
[2] IDISNA, Navarra Hlth Serv, Complejo Hosp Navarra, Dept Hematol, Navarra, Spain
[3] Complejo Hospitalario Navarra, Immun Unit, Navarra Hlth Serv, IDISNA, Pamplona, Spain
[4] Imperial Coll Healthcare NHS, Hammersmith Hosp, London, England
关键词
CMV-specific T cells; Allogeneic HSCT; Immune monitoring; CD8(+) T-CELLS; BONE-MARROW TRANSPLANT; ENZYME-LINKED IMMUNOSPOT; IFN-GAMMA CD8(+); HUMAN NK CELLS; RISK-FACTORS; CMV INFECTION; LYMPHOCYTE RESPONSES; PREEMPTIVE THERAPY; IDENTIFY PATIENTS;
D O I
10.1007/s00018-015-1986-z
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Approximately, up to 70 % of the human population is infected with cytomegalovirus (CMV) that persists for life in a latent state. In healthy people, CMV reactivation induces the expansion of CMV-specific T cells up to 10 % of the entire T cell repertoire. On the contrary, CMV infection is a major opportunistic viral pathogen that remains a leading cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. Due to the delayed CMV-specific immune recovery, the incidence of CMV reactivation during post-transplant period is very high. Several methods are currently available for the monitoring of CMV-specific responses that help in clinical monitoring. In this review, essential aspects in the immune recovery against CMV are discussed to improve the better understanding of the immune system relying on CMV infection and, thereby, helping the avoidance of CMV disease or reactivation following hematopoietic stem cell transplantation with severe consequences for the transplanted patients.
引用
收藏
页码:4049 / 4062
页数:14
相关论文
共 50 条
  • [1] The immune response to cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients
    Miriam Ciáurriz
    Amaya Zabalza
    Lorea Beloki
    Cristina Mansilla
    Estela Pérez-Valderrama
    Mercedes Lachén
    Eva Bandrés
    Eduardo Olavarría
    Natalia Ramírez
    Cellular and Molecular Life Sciences, 2015, 72 : 4049 - 4062
  • [2] Cytomegalovirus Management in Allogeneic Hematopoietic Stem Cell Transplant Recipients
    Barlow, Ashley
    US PHARMACIST, 2021, 46 (04)
  • [3] Management of Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients
    Silva, Fernando
    Martins, Antonio
    Ferraz, Paula
    Lopes, Diogo
    Bastos, Juliana
    Araujo, Joana
    Trigo, Fernanda
    Pinto, Ricardo
    Silva-pinto, Andre
    ACTA MEDICA PORTUGUESA, 2024, 37 (10) : 733 - 740
  • [4] GENOTYPING OF HUMAN CYTOMEGALOVIRUS (HCMV) IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS
    Dieamant, D. C.
    Bonon, S. H. A.
    Murakami, M. M.
    Costa, S. C. B.
    Vigorito, A. C.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (02) : S277 - S278
  • [5] Human Cytomegalovirus Latency and Reactivation in Allogeneic Hematopoietic Stem Cell Transplant Recipients
    Stern, Lauren
    Withers, Barbara
    Avdic, Selmir
    Gottlieb, David
    Abendroth, Allison
    Blyth, Emily
    Slobedman, Barry
    FRONTIERS IN MICROBIOLOGY, 2019, 10
  • [6] Immune Deficits in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients
    Mir, Muhammad A.
    Battiwalla, Minoo
    MYCOPATHOLOGIA, 2009, 168 (06) : 271 - 282
  • [7] Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients
    Ljungman, Per
    Hakki, Morgan
    Boeckh, Michael
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2011, 25 (01) : 151 - +
  • [8] Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients
    Ljungman, Per
    Hakki, Morgan
    Boeckh, Michael
    INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2010, 24 (02) : 319 - +
  • [9] Immune Deficits in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients
    Muhammad A. Mir
    Minoo Battiwalla
    Mycopathologia, 2009, 168 : 271 - 282
  • [10] Cost Effectiveness of Letermovir as Cytomegalovirus Prophylaxis in in Allogeneic Hematopoietic Stem Cell Transplant Recipients
    Schelfhout, Jonathan
    Jiang, Yiling
    Miles, LaStella
    Merchant, Sanjay
    Graham, Jonathan
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (03) : S384 - S384